t
| Date | 18 Jan 2024 |
| Time | 07:00:07 |
| Category | Corporate updates |
| ID | 0705A |
NIOX GROUP PLC
("NIOX" or the "Company")
Appointment of Financial Adviser and Joint Broker
Oxford, UK - 18 January 2024: NIOX Group plc (AIM: NIOX), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, today announces the appointment of Investec Bank plc as the Company's financial adviser and joint broker with immediate effect. Singer Capital Markets continues to act as the Company's nominated adviser and corporate broker.
Contacts
|
NIOX |
Tel: +44 (0) 1865 405 560 |
|
Ian Johnson, Executive Chairman |
|
|
Michael Roller, Chief Financial Officer |
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and joint broker) |
Tel: +44 (0) 20 7496 3000 |
|
Aubrey Powell / Jen Boorer / Alaina Wong |
|
|
|
|
|
Investec Bank plc |
Tel: +44 (0) 20 7597 4000 |
|
Edward Knight / Bruce Garrow / Lydia Zychowska |
|
About NIOX
Our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies.
NIOX provides products and services via its direct sales organisation and extensive distributor network in 50 countries. For more information, please visit www.niox.com